A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.
The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Owen Witte with the twelfth annual Harrington Prize for Innovation in Medicine.
